Melatonin and renal protection: Novel perspectives from animal experiments and human studies (review)

Current Pharmaceutical Design

Volumn 21, Issue 7, 2015, Pages 936-949

  Hrenak, Jaroslav ^a   Paulis, Ludovit ^a,b   Repova, Kristina ^a   Aziriova, Silvia ^a   Nagtegaal, Elsbeth J ^c   Reiter, Russel J ^d   Simko, Fedor ^a,e,f  

^a Faculty of Natural Sciences   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c MEANDER MEDICAL CENTER   (Netherlands)

^d University of Texas Health Science Center   (United States)

^e INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^f Center of Excellence NOREG   (Slovakia)

Author keywords

Chronic kidney disease; Fibrosis; Melatonin; Oxidative stress; Protection; Proteinuria

Indexed keywords

INDOLEAMINE; IRON; MELATONIN; MELATONIN RECEPTOR; SCAVENGER;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL PROTECTION; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CHRONOBIOLOGY; DRUG EFFICACY; DRUG RECEPTOR BINDING; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL DIABETIC NEUROPATHY; EXPERIMENTAL HYPERTENSION; GLOMERULONEPHRITIS; HEMODIALYSIS PATIENT; HEMORRHAGIC SHOCK; HUMAN; IRON METABOLISM; KIDNEY FIBROSIS; KIDNEY PARENCHYMA; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PINEAL BODY; PRIORITY JOURNAL; PROTEINURIA; PYELONEPHRITIS; RENAL PROTECTION; SIGNAL TRANSDUCTION; SLEEP DISORDER; ANIMAL; ANIMAL MODEL; DRUG EFFECTS; KIDNEY; METABOLISM; PATHOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; HUMANS; KIDNEY; MELATONIN; MODELS, ANIMAL; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION;

EID: 84925869773     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140929092929     Document Type: Article

References (191)

1. [1] Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 2010; 268: 456-67.
2. [2] Schlondorff, D. O. Overview of factors contributing to the pathophysiology of progressive renal disease. Kidney Int 2008; 74: 860-6.
3. [3] Jafar TH, Stark PC, Schmid CH, et al. AIPRD Study Group. Angiotensin-Converting Enzyme Inhibition and Progression of Renal Disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131-40.
4. [4] Grimm RH Jr, Svendsen KH, Kasiske B, Keane WF, Wahi MM. MRFIT Research Group. Multiple risk Factor Intervention. Proteinuria is a risk factor for mortality over 10 years of follow-up. Trial. Kidney Int 1997; 63 (Suppl 1): S10-4.
5. [5] Guerrero-Romero F, Rodriguez-Moran M. Proteinuria is an independent risk factor for ischemic stroke in non-insulin-dependent diabetes mellitus. Stroke 1999; 30: 1787-91.
6. [6] Reiter RJ, Tan DX, Rosales-Corral S, Manchester LC. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev Med Chem 2013; 13: 373-84.
7. [7] Roopin M, Levy O. Temporal and histological evaluation of melatonin patterns in a 'basal' metazoan. J Pineal Res 2012; 53: 259-69.
8. [8] Mercolini L, Mandrioli R, Raggi MA. Content of melatonin and other antioxidants in grape-related foodstuffs: measurement using a MEPS-HPLC-F method. J Pineal Res 2012; 53: 21-8.
9. [9] Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/ nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
10. [10] Kvetnoy I. Extrapineal melatonin in pathology: new perspectives for diagnosis, prognosis and treatment of illness. Neuro Endocrinol Lett 2002; 23 (Suppl 1): 92-6.
11. [11] Tan DX, Manchester LC, Hardeland R, et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003; 34: 75-8.
12. [12] Carrillo-Vico, Calvo JR, Abreu P, et al. Evidence of melatonin synthesis in human lymphocytes and its physiological significance: possible role as intracrine, autocrine and/or paracrine substance. FASEB J 2004; 18: 537-9.
13. [13] Reiter RJ, Rosales-Corral S, Coto-Montes A, et al. The photoperiod, circadian regulation and chronodisruption: the requisite interplay between the suprachiasmatic nuclei and the pineal and gut melatonin. J Physiol Pharmacol 2011; 62: 269-74.
14. [14] Pevet P, Challet E. Melatonin: both master clock output and internal time-giver in the circadian clocks network. J Physiol Paris 2011; 105: 170-82.
15. [15] Hardeland R, Madrid JA, Tan DX, Reiter RJ. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res 2012; 52: 139-66.
16. [16] Barrett P, Bolborea M. Molecular pathways involved in seasonal body weight and reproductive responses governed by melatonin. J Pineal Res 2012; 52: 376-88.
17. [17] Reiter RJ, Tan DX, Fuentes-Broto L. Melatonin: a multitasking molecule. Prog Brain Res 2010; 181: 127-51.
18. [18] Chattoraj A, Liu T, Zhang LS, Huang Z, Borjigin J. Melatonin formation in mammals: in vivo perspectives. Rev Endocr Metab Disord 2009; 10: 237-43.
19. [19] Skene DJ, Arendt J. Human circadian rhythms: physiological and therapeutic relevance of light and melatonin. Ann Clin Biochem 2006; 43: 344-53.
20. [20] Pandi-Perumal SR, Trakht I, Srinivasan V, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008; 85: 335-53.
21. [21] Waldhauser F, Kovács J, Reiter E. Age-related changes in melatonin levels in humans and its potential consequences for sleep disorders. Exp Gerontol 1998; 33: 759-72.
22. [22] Reiter RJ. The ageing pineal gland and its physiological consequences. Bioessays 1992; 14: 169-75.
23. [23] Potocki L, Glaze D, Tan DX, et al. Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome. J Med Genet 2000; 37: 428-33.
24. [24] Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin--a pleiotropic, orchestrating regulator molecule. Prog Neurobiol 2011; 93: 350-84.
25. [25] Gitto E, Pellegrino S, Gitto P, Barberi I, Reiter RJ. Oxidative stress of the newborn in the pre-and postnatal period and the clinical utility of melatonin. J Pineal Res 2009; 46: 128-39.
26. [26] Stankov B, Reiter RJ. Melatonin receptors: current status, facts, and hypotheses. Life Sci 1990; 46: 971-82.
27. [27] Paulis L, Simko F, Laudon M. Cardiovascular effects of melatonin receptor agonists. Expert Opin Investig Drugs 2012; 21:1661-78.
28. [28] Nosjean O, Ferro M, Coge F, et al. Identification of the melatoninbinding site MT3 as the quinone reductase 2. J Biol Chem 2000; 275: 31311-7.
29. [29] Delagrange P and Boutin JA. Therapeutic potential of melatonin ligands. Chronobiol Int 2003; 23: 413-8.
30. [30] Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol 2012; 351: 152-66.
31. [31] Benítez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 2006; 40: 1-9.
32. [32] Martín M, Macías M, Escames G, et al. Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res 2000; 28: 242-8.
33. [33] Martín M, Macías M, León J, Escames G, Khaldy H, Acuña-Castroviejo D. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 2002; 34: 348-57.
34. [34] Escames G, López LC, Tapias V, et al. Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J Pineal Res 2006; 40: 71-8.
35. [35] Reiter RJ, Paredes SD, Korkmaz A, Jou MJ, Tan DX. Melatonin combats molecular terrorism at the mitochondrial level. Interdiscip Toxicol 2008; 1: 137-49.
36. [36] Tan DX, Chen LD, Poeggeler B, et al. 1993. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocrine J 1993; 1: 57-60.
37. [37] Reiter RJ, Manchester LC, Fuentes-Broto L, Tan DX. Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin. J Hypertens 2010b; 28 (Suppl 1): S7-12.
38. [38] Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res. 2007; 42: 28-42.
39. [39] Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res 2013; 54: 245-57.
40. [40] Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 1-9.
41. [41] Barlow-Walden LR, Reiter RJ, Abe M, et al. Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995; 26: 497-502.
42. [42] Pablos MI, Reiter RJ, Ortiz GG, et al. Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light. Neurochem Int 1998; 32: 69-75.
43. [43] Limón-Pacheco JH, Gonsebatt ME. The glutathione system and its regulation by neurohormone melatonin in the central nervous system. Cent Nerv Syst Agents Med Chem 2010; 10: 287-97.
44. [44] Urata Y, Honma S, Goto S, et al. Melatonin induces gammaglutamylcysteine synthase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med 1999; 27: 838-47.
45. [45] Gitto E, Tan DX, Reiter RJ, et al. Individual and synergistic actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferoxamine in liver homogenates. J Pharm Pharmacol 2001; 53: 1393-401.
46. [46] Lopez-Burillo S, Tan DX, Mayo JC, Sainz RM, Manchester LC, Reiter RJ. Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and alpha-lipoic acid differentially reduce oxidative DNA dam age induced by Fenton reagents: a study of their individual and synergistic actions. J Pineal Res 2003; 34: 269-77.
47. [47] Romero A, Egea J, García AG, López MG. Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells. J Pineal Res 2010; 49: 141-8.
48. [48] Kwon KJ, Kim HJ, Shin CY, Han SH. Melatonin Potentiates the Neuroprotective Properties of Resveratrol Against Beta-Amyloid-Induced Neurodegeneration by Modulating AMP-Activated Protein Kinase Pathways. J Clin Neurol 2010; 6: 127-37.
49. [49] Tan DX, Manchester LC, Reiter RJ, et al. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta 1999; 1472: 206-14.
50. [50] Conti S, Conconi E, Hertens K, Skwarlo-Sonta K, Markowska M, Maestroni JM. Evidence for melatonin synthesis in mouse and human bone marrow cells. J. Pineal Res 2000; 28: 193-202.
51. [51] Maldonado MD, Mora-Santos M, Naji L, Carrascosa-Salmoral MP, Naranjo MC, Calvo JR. Evidence of melatonin synthesis and release by mast cells. Possible modulatory role on inflammation. Pharmacol Res 2010; 62: 282-7.
52. [52] Lardone PJ, Guerrero JM, Fernández-Santos JM, Rubio A, Martín-Lacave I, Carrillo-Vico A. Melatonin synthesized by T lymphocytes as a ligand of the retinoic acid-related orphan receptor. J Pineal Res 2011; 51: 454-62.
53. [53] Ahmad R, Haldar C, Gupta S. Melatonin membrane receptor type MT1 modulates cell-mediated immunity in the seasonally breeding tropical rodent Funambulus pennanti. Neuroimmunomodulation 2012; 19: 50-9.
54. [54] Pozo D, Delgado M, Fernandez-Santos JM, et al. Expression of the Mel1a-melatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen. FASEB J 1997; 11: 466-73.
55. [55] Markowska M, Mrozkowiak A, Skwarlo-Sonta K. Influence of melatonin on chicken lymphocytes in vitro: involvement of membrane receptors. Neuro Endocrinol Lett 2002; 23 (Suppl 1): 67-72.
56. [56] Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200.
57. [57] Radogna F, Diederich M, Ghibelli L. Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol 2010; 80: 1844-52.
58. [58] Mauriz JL, Collado PS, Veneroso C, Reiter RJ, González-Gallego J. A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. J Pineal Res 2013; 54: 1-14.
59. [59] Sanz AB, Santamaría B, Ruiz-Ortega M, Egido J, Ortiz A. 2008. Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol 2008; 19: 1634-42.
60. [60] Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, Reiter RJ. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 2003; 60: 1407-26.
61. [61] Leja-Szpak A, Jaworek J, Pierzchalski P, Reiter RJ. Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res 2010; 49: 248-55.
62. [62] Wang J, Xiao X, Zhang Y, et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 2012; 53: 77-90.
63. [63] Uguz AC, Cig B, Espino J, et al. Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells. J Pineal Res 2012; 53: 91-8.
64. [64] Paulis L, Pechanova O, Zicha J, et al. Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats. J Hypertens Suppl 2009; 27(Suppl 6):S11-6.
65. [65] Simko F, Pechanova O, Pelouch V, et al. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J Hypertens 2009; 27(Suppl 6):S5-10.
66. [66] Simko F, Pechanova O. Remodelling of the heart and vessels in experimental hypertension: advances in protection. J Hypertens 2010; 28 (Suppl 1):S1-6.
67. [67] Dominguez-Rodriguez A. Melatonin in cardiovascular disease. Expert Opin Investig Drugs 2012a; 21: 1593-1596.
68. [68] Dominguez-Rodriguez A, Abreu-Gonzalez P, Arroyo-Ucar E, Reiter RJ. Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction. J Pineal Res 2012b; 53: 319-23.
69. [69] Dominguez-Rodriguez A, Abreu-Gonzalez P. Myocardial ischemiareperfusion injury: Possible role of melatonin. World J Cardiol 2010; 2: 233-6.
70. [70] Simko F, Paulis L. Antifibrotic effect of melatonin-Perspective protection in hypertensive heart disease. Int J Cardiol 2013; 20.[Epub ahead of print].
71. [71] Tahan G, Akin H, Aydogan F, et al. Melatonin ameliorates liver fibrosis induced by bile-duct ligation in rats. Can J Surg 2010; 53: 313-318.
72. [72] Yildirim Z, Kotuk M, Erdogan H, et al. Preventive effect of melatonin on bleomycin-induced lung fibrosis in rats. J Pineal Res 2006; 40: 27-33.
73. [73] Kim GD, Lee SE, Kim TH, Jin YH, Park YS, Park CS. Melatonin suppresses acrolein-induced IL-8 production in human pulmonary fibroblasts. J Pineal Res 2012; 52: 356-64.
74. [74] Aust S, Jäger W, Kirschner H, Klimpfinger M, Thalhammer T. Pancreatic stellate/myofibroblast cells express G-protein-coupled melatonin receptor 1. Wien Med Wochenschr 2008; 158: 575-8.
75. [75] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl 1):S1-S266.
76. [76] Reiter RJ, Tan DX, Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact on hypertension. J Hypertens 2009; 27 (Suppl 6):S17-20.
77. [77] Simko F, Pechanova O. Recent trends in hypertension treatment: perspectives from animal studies. J Hypertens 2009; 27 (Suppl 6): S1-4.
78. [78] Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res 2007; 42:319-22.
79. [79] Simko F, Paulis L. Chronotherapy beyond blood pressure reduction? J Pineal Res 2008; 45: 227-8.
80. [80] Simko F. Chronobiology of blood pressure: emerging implications of melatonin. Eur J Clin Invest 2012; 42: 1252-4.
81. [81] Simko F, Reiter RJ, Pechanova O, Paulis L. Experimental models of melatonin-deficient hypertension. Front Biosci 2013; 18: 616-25.
82. [82] Zanoboni A, Zanoboni-Muciaccia W. Experimental hypertension in pinealectomized rats. Life Sci 1967; 6: 2327-31.
83. [83] Zanoboni A, Forni A, Zanoboni-Muciaccia W, et al. Effect of pinealectomy on arterial blood pressure and food and water intake in the rat. J Endocrinol Invest 1978; 1: 125-30.
84. [84] Karppanen H, Vapaatalo H, Lahovaara S, et al. Studies with pinealectomized rats. Potential protective effect of melatonin has been studied in several models of hypertension. Pharmacology 1970; 3: 76-84.
85. [85] Briaud SA, Zhang BL, Sannajust F. Continuous light exposure and sympathectomy suppress circadian rhythm of blood pressure in rats. J Cardiovasc Pharmacol Ther 2004; 9: 97-105.
86. [86] Simko F, Pechanova O, Pelouch V, et al. Continuous light and LNAME-induced left ventricular remodelling: different protection with melatonin and captopril. J Hypertens 2010; 28 (Suppl 1): S13-8.
87. [87] Holmes SW, Sugden D. Proceedings. The effect of melatonin on pinealectomy-induced hypertension in the rat. Br J Pharmacol 1976; 56: 360P-1.
88. [88] Pechánová O, Zicha J, Paulis L, et al. The effect of Nacetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur J Pharmacol 561: 129-36.
89. [89] Rezzani R, Porteri E, De Ciuceis C, et al. Effects of melatonin and Pycnogenol on small artery structure and function in spontaneously hypertensive rats. Hypertension 2010; 55: 1373-80.
90. [90] Lee IC, Kim SH, Lee SM, et al. Melatonin attenuates gentamicininduced nephrotoxicity and oxidative stress in rats. Arch Toxicol 2012; 86: 1527-36.
91. [91] Paulis L, Pechanova O, Zicha J, et al. Melatonin interactions with blood pressure and vascular function during L-NAME-induced hypertension. J Pineal Res 2010a; 48: 102-8.
92. [92] Paulis L, Pechanova O, Zicha J, et al. Melatonin improves the restoration of endothelium-derived constricting factor signalling and inner diameter in the rat femoral artery after cessation of L-NAME treatment. J Hypertens 2010b; 28 (Suppl 1): S19-24.
93. [93] Leibowitz A, Peleg E, Sharabi Y, Shabtai Z, Shamiss A, Grossman E.The role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome. Am J Hypertens 2008; 21: 348-51.
94. [94] Xia CM, Shao CH, Xin L, et al. Effects of melatonin on blood pressure in stress-induced hypertension in rats. Clin Exp Pharmacol Physiol 2008; 35: 1258-64.
95. [95] Koziróg M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. Pineal Res 2011; 50: 261-6.
96. [96] Scheer FA, Van Montfrans GA, van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004; 43: 192-7
97. [97] Cavallo A, Daniels SR, Dolan LM, Khoury JC, Bean JA. Blood pressure response to melatonin in type 1 diabetes. Pediatr Diabetes 2004; 5: 26-31.
98. [98] Grossman E, Laudon M, Yalcin R, et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med 2006; 119: 898-902.
99. [99] Cagnacci A, Cannoletta M, Renzi A, Baldassari F, Arangino S, Volpe A. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hypertens 2005; 18: 1614-8.
100. [100] Rechciński T, Trzos E, Wierzbowska-Drabik K, Krzemi_ska-Paku_a M, Kurpesa M. Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability. Hypertens Res 2010; 33: 56-61.
101. [101] Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag 2011; 7: 577-84.
102. [102] Er ahin M, Sehirli O, Toklu HZ, et al. Melatonin improves cardiovascular function and ameliorates renal, cardiac and cerebral damage in rats with renovascular hypertension. J Pineal Res 2009; 47: 97-106.
103. [103] Rodríguez-Iturbe B, Quiroz Y, Nava M, et al. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 2002; 282: F191-201.
104. [104] Nava M, Quiroz Y, Vaziri N, Rodriguez-Iturbe B. Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. 2003. Am J Physiol Renal Physiol 2003; 284: F447-54.
105. [105] Tain YL, Huang LT, Lin IC, Lau YT, Lin CY. Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats. J Pineal Res 2010; 49: 390-8.
106. [106] Ilhan S, Atessahin D, Atessahin A, Mutlu E, Onat E, Sahna E. 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin-incuded hypertension: The beneficial effects of melatonin. Toxicol Ind Health 2013; 23.[Epub ahead of print].
107. [107] La Fleur SE, Kalsbeek A, Wortel J, van der Vliet J, Buijs RM. Role for the pineal and melatonin in glucose homeostasis: pinealectomy increases night-time glucose concentrations. J Neuroendocrinol 2001; 13: 1025-32.
108. [108] Reiter RJ, Tan DX, Korkmaz A, Ma S. Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. Ann Med 2012; 44: 564-77.
109. [109] Frese T, Bach AG, Mühlbauer E, et al. Pineal melatonin synthesis is decreased in type 2 diabetic Goto-Kakizaki rats. Life Sci 2009; 85:526-33.
110. [110] Peschke E, Frese T, Chankiewitz E, et al. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res 2006; 40: 135-43.
111. [111] Peschke E, Stumpf I, Bazwinsky I, Litvak L, Dralle H, Mühlbauer E. Melatonin and type 2 diabetes-a possible link? J Pineal Res 2007; 42: 350-358.
112. [112] Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes 2011; 4: 307-13.
113. [113] Ha E, Yim SV, Chung JH, et al. Melatonin stimulates glucose transport via insulin receptor substrate-1/phosphatidylinositol 3-kinase pathway in C2C12 murine skeletal muscle cells. J Pineal Res 2006; 41: 67-72.
114. [114] Ghosh G, De K, Maity S, et al. Melatonin protects against oxidative damage and restores expression of GLUT4 gene in the hyperthyroid rat heart. J Pineal Res 2007; 42: 71-82.
115. [115] Agil A, Navarro-Alarcón M, Ruiz R, Abuhamadah S, El-Mir MY, Vázquez GF. Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. J Pineal Res 2011; 50: 207-12.
116. [116] de Oliveira AC, Andreotti S, Farias Tda S, et al. Metabolic disorders and adipose tissue insulin responsiveness in neonatally STZinduced diabetic rats are improved by long-term melatonin treatment. Endocrinology 2012; 153: 2178-88.
117. [117] Agil A, Rosado I, Ruiz R, Figueroa A, Zen N, Fernández-Vázquez G. Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res 2012; 52: 203-10.
118. [118] Robeva R, Kirilov G, Tomova A, Kumanov P. Melatonin-insulin interactions in patients with metabolic syndrome. J Pineal Res 2008; 44: 52-6.
119. [119] Tamura H, Nakamura Y, Narimatsu A, et al. Melatonin treatment in peri-and postmenopausal women elevates serum high-density lipoprotein cholesterol levels without influencing total cholesterol levels. J Pineal Res 2008; 45: 101-5.
120. [120] Stebelová K, Herichová I, Zeman M. Diabetes induces changes in melatonin concentrations in peripheral tissues of rat. Neuro Endocrinol Lett 2007; 28: 159-65.
121. [121] Ha H, Yu MR, Kim KH. Melatonin and taurine reduce early glomerulopathy in diabetic rats. Free Radic Biol Med 1999; 26: 944-50.
122. [122] Aksoy N, Vural H, Sabuncu T, Aksoy S. Effects of melatonin on oxidative-antioxidative status of tissues in streptozotocin-induced diabetic rats. Cell Biochem Funct 2003; 21: 121-5.
123. [123] Anwar MM, Meki AR. Oxidative stress in streptozotocin-induced diabetic rats: effects of garlic oil and melatonin. Comp Biochem Physiol A Mol Integr Physiol 2003; 135: 539-47.
124. [124] Oktem F, Ozguner F, Yilmaz HR, Dündar B. Melatonin reduces urinary excretion of N-acetyl-beta-D-glucosaminidase, albumin and renal oxidative markers in diabetic rats. Clin Exp Pharmacol Physiol 2006; 33: 95-101.
125. [125] Gumustekin M, Tekmen I, Guneli E, et al. Short-term melatonin treatment improved diabetic nephropathy but did not affect hemorheological changes in diabetic rats. Pharmazie 2007; 62: 693-8.
126. [126] Cam M, Yavuz O, Guven A, Ercan F, Bukan N, Ustündag N. Protective effects of chronic melatonin treatment against renal injury in streptozotocin-induced diabetic rats. J Pineal Res 2003; 35: 212-20.
127. [127] Baydas G, Canatan H, Turkoglu A. Comparative analysis of the protective effects of melatonin and vitamin E on streptozocininduced diabetes mellitus. J Pineal Res 2002; 32: 225-30.
128. [128] Kurcer Z, Parlakpinar H, Vardi N, et al. Protective effects of chronic melatonin treatment against renal ischemia/reperfusion injury in streptozotocin-induced diabetic rats. Exp Clin Endocrinol Diabetes 2007; 115: 365-371.
129. [129] Fadillioglu E, Kurcer Z, Parlakpinar H, Iraz M, Gursul C. Melatonin treatment against remote organ injury induced by renal ischemia reperfusion injury in diabetes mellitus. Arch Pharm Res 2008; 31: 705-12.
130. [130] Hara M, Yoshida M, Nishijima H, et al. Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatininduced nephrotoxicity in rats. J Pineal Res 2001; 30: 129-38.
131. [131] Sener G, Satiroglu H, Kabasakal L, et al. The protective effect of melatonin on cisplatin nephrotoxicity. Fundam Clin Pharmacol 2000; 14: 553-60.
132. [132] Kilic U, Kilic E, Tuzcu Z, et al. Melatonin suppresses cisplatininduced nephrotoxicity via activation of Nrf-2/HO-1 pathway. Nutr Metab (Lond) 2013; 12:7.
133. [133] Jahovic N, Cevik H, Sehirli AO, Yeen BC, Sener G. Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats. J Pineal Res 2003; 34: 282-7.
134. [134] Abraham P, Kolli VK, Rabi S. Melatonin attenuates methotrexateinduced oxidative stress and renal damage in rats. Cell Biochem Funct 2010; 28: 426-33.
135. [135] Oz E, Ilhan MN. Effects of melatonin in reducing the toxic effects of doxorubicin. Mol Cell Biochem 2006; 286: 11-5.
136. [136] Montilla P, Túnez I, Muñoz MC, López A, Soria JV. Hyperlipidemic nephropathy induced by adriamycin: effect of melatonin administration. Nephron 1997; 76: 345-50.
137. [137] Agapito MT, Antolín Y, del Brio MT, López-Burillo S, Pablos MI, Recio JM. Protective effect of melatonin against adriamycin toxicity in the rat. J Pineal Res 2001; 31: 23-30.
138. [138] Dziegiel P, Suder E, Surowiak P, et al. Role of exogenous melatonin in reducing the nephrotoxic effect of daunorubicin and doxorubicin in the rat. J Pineal Res 2002; 33: 95-100.
139. [139] Omurtag GZ, Tozan A, Sehirli AO, Sener G. Melatonin protects against endosulfan-induced oxidative tissue damage in rats. J Pineal Res 2008; 44: 432-8.
140. [140] Kunak ZI, Macit E, Yaren H, et al. Protective Effects of Melatonin and S-Methylisothiourea on Mechlorethamine Induced Nephrotoxicity. J Surg Res 2012; 175: e17-23.
141. [141] Shin YH, Lee SH, Mun KC. Effect of melatonin on the antioxidant enzymes in the kidneys of cyclosporine-treated rats. Transplant Proc 2002; 34: 2650-51.
142. [142] Chang EJ, Mun KC. Effect of melatonin on the malondialdehyde level of neutrophils in cyclosporine-treated rats. Transplant Proc 2004; 36: 2165-6.
143. [143] Eşrefoğlu M, Kuruş M, Sahna E. The beneficial effect of melatonin on chronic cyclosporin a nephrotoxicity in rats. J Int Med Res 2003; 31: 42-4
144. [144] Stacchiotti A, Lavazza A, Rezzani R, Bianchi R. Cyclosporine Ainduced kidney alterations are limited by melatonin in rats: an electron microscope study. Ultrastruct Pathol 2002a; 26: 81-7.
145. [145] Kumar KV, Naidu MU, Shifow AA, Prayag A, Ratnakar KS. Melatonin: an antioxidant protects against cyclosporine-induced nephrotoxicity. Transplantation 1999; 67:1065-608.
146. [146] Mun KC, Suh SI. Effect of melatonin on renal function in cyclosporine nephrotoxicity. Transplant Proc 2000; 32: 1919-20.
147. [147] Longoni B, Migliori M, Ferretti A, et al. Melatonin prevents cyclosporine-induced nephrotoxicity in isolated and perfused rat kidney. Free Radic Res 2002; 36: 357-63.
148. [148] Stacchiotti A, Rezzani R, Angoscini P, Rodella L, Bianchi R. Small heat shock proteins expression in rat kidneys treated with cyclosporine a alone and combined with melatonin. Histochem J 2002b; 34: 305-12.
149. [149] Ozbek E, Turkoz Y, Sahna E, Ozugurlu F, Mizrak B, Ozbek M. Melatonin administration prevents the nephrotoxicity induced by gentamicin. BJU Int 2000; 85: 742-74.
150. [150] Sener G, Sehirli AO, Altunbas HZ, et al. Melatonin protects against gentamicin-induced nephrotoxicity in rats. J Pineal Res 2002; 32: 231-6.
151. [151] Shifow AA, Kumar KV, Naidu MU, Ratnakar KS. Melatonin, a pineal hormone with antioxidant property, protects against gentamicin-induced nephrotoxicity in rats. Nephron 2000; 85: 167-74.
152. [152] Ogeturk M, Kus I, Kavakli A, Oner J, Kukner A, Sarsilmaz M. Reduction of carbon tetrachloride-induced nephropathy by melatonin administration. Cell Biochem Funct 2005; 23: 85-92.
153. [153] Pedreañez A, Rincón J, Romero M, Viera N, Mosquera J. Melatonin decreases apoptosis and expression of apoptosis-associated proteins in acute puromycin aminonucleoside nephrosis. Nephrol Dial Transplant 2004; 19: 1098-105.
154. [154] Aydin G, Ozçelik N, Ciçek E, Soyöz M. Histopathologic changes in liver and renal tissues induced by Ochratoxin A and melatonin in rats. Hum Exp Toxicol 2003; 22: 383-91.
155. [155] Bellés M, Linares V, Luisa Albina M, Sirvent J, Sánchez DJ, Domingo JL. Melatonin reduces uranium-induced nephrotoxicity in rats. J Pineal Res 2007; 43: 87-95.
156. [156] Ilbey YO, Ozbek E, Cekmen M, et al. Melatonin prevents acetaminophen-induced nephrotoxicity in rats. Int Urol Nephrol 2009; 41: 695-702.
157. [157] Yousef JM, Chen G, Hill PA, Nation RL, Li J. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 2011; 55: 4044-9.
158. [158] Ozan E, Sonmez MF, Ozan S, Colakoglu N, Yilmaz S, Kuloglu T. Effects of melatonin and vitamin C on cigarette smoke-induced damage in the kidney. Toxicol Ind Health 2007; 23: 479-85.
159. [159] Sönmez MF, Narin F, Akku_ D, Türkmen AB. Melatonin and Vitamin C Ameliorate Alcohol-Induced Oxidative Stress and eNOS Expression in Rat Kidney. Ren Fail 2012; 34: 480-6.
160. [160] Oktem F, Ozguner F, Mollaoglu H, Koyu A, Uz E. Oxidative damage in the kidney induced by 900-MHz-emitted mobile phone: protection by melatonin. Arch Med Res 2005; 36: 350-5.
161. [161] Kucuktulu E. Protective effect of melatonine against radiation induced nephrotoxicity in rats. Asian Pac J Cancer Prev 2012; 13: 4101-5.
162. [162] Li Z, Nickkholgh A, Yi X, et al. Melatonin protects kidney grafts from ischemia/reperfusion injury through inhibition of NF-B and apoptosis after experimental kidney transplantation. J Pineal Res 2009; 46: 365-72.
163. [163] Kunduzova OR, Escourrou G, Seguelas MH, et al. Prevention of apoptotic and necrotic cell death, caspase-3 activation, and renal dysfunction by melatonin after ischemia/reperfusion. FASEB J 2003; 17: 872-4.
164. [164] Sinanoglu O, Sezgin G, Ozturk G, et al. Melatonin with 1,25-dihydroxyvitamin D3 protects against apoptotic ischemiareperfusion injury in the rat kidney. Ren Fail 2012; 34: 1021-6.
165. [165] Patschan D, Hildebrandt A, Rinneburger J, et al. The hormone melatonin stimulates renoprotective effects of "early outgrowth" endothelial progenitor cells in acute ischemic kidney injury. Am J Physiol Renal Physiol 2012; 302: F1305-12.
166. [166] Atilgan D, Parlaktas BS, Uluocak N, et al. Effects of melatonin on partial unilateral ureteral obstruction induced oxidative injury in rat kidney. Urol Ann 2012; 4: 89-93.
167. [167] Ozbek E, Ilbey YO, Ozbek M, Simsek A, Cekmen M, Somay A. Melatonin attenuates unilateral ureteral obstruction-induced renal injury by reducing oxidative stress, iNOS, MAPK, and NF-B expression. J Endourol 2009; 23: 1165-73.
168. [168] Quiroz Y, Ferrebuz A, Romero F, Vaziri ND, Rodriguez-Iturbe B. Melatonin ameliorates oxidative stress, inflammation, proteinuria, and progression of renal damage in rats with renal mass reduction. Am J Physiol Renal Physiol 2007; 294: F336-44.
169. [169] Sener G, Paskaloglu K, Toklu H, et al. Melatonin ameliorates chronic renal failure-induced oxidative organ damage in rats. J Pineal Res 2004; 36: 232-41.
170. [170] Hung MW, Kravtsov GM, Lau CF, Poon AM, Tipoe GL, Fung ML. Melatonin ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in rats with chronic intermittent hypoxia. J Pineal Res 2013; 55: 247-56.
171. [171] Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, Reiter RJ. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 2003; 60: 1407-26.
172. [172] Sener G, Tuğtepe H, Velioğlu-Oğünç A, Cetinel S, Gedik N, Ye_en BC. Melatonin prevents neutrophil-mediated oxidative injury in Escherichia coli-induced pyelonephritis in rats. J Pineal Res 2006; 41: 220-7.
173. [173] Wu CC, Lu KC, Lin GJ, et al. Melatonin enhances endogenous heme oxygenase-1 and represses immune responses to ameliorate experimental murine membranous nephropathy. J Pineal Res 2012; 52: 460-9.
174. [174] Yang FL, Subeq YM, Lee CJ, Lee RP, Peng TC, Hsu BG. Melatonin ameliorates hemorrhagic shock-induced organ damage in rats. J Surg Res 2011; 167:e315-21.
175. [175] Kim YH, Lee SH, Mun KC. Effect of melatonin on antioxidant status in the plasma of cyclosporine-treated rats. Transplant Proc 2002; 34: 2652-3265.
176. [176] Eybl V, Kotyzová D, Cerná P, Koutensky J. Effect of melatonin, curcumin, quercetin, and resveratrol on acute ferric nitrilotriacetate (Fe-NTA)-induced renal oxidative damage in rats. Hum Exp Toxicol 2008; 27: 347-53.
177. [177] Sezgin G, Oztürk G, Güney S, Sinanoğlu O, Tunçdemir M. Protective effect of melatonin and 1,25-dihydroxyvitamin D3 on renal ischemia-reperfusion injury in rats. Ren Fail 2013; 35: 374-9.
178. [178] Lerchl A, Reiter RJ. Treatment of sleep disorders with melatonin. BMJ 2012; 5: e6968.
179. [179] Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. J Pineal Res 2012; 52: 365-75.
180. [180] Russcher M, Koch B, Nagtegaal E, van der Putten K, ter Wee P, Gaillard C. The role of melatonin treatment in chronic kidney disease. Front Biosci 2012; 17: 2644-56.
181. [181] Aperis G, Prakash P, Paliouras C, Papakonstantinou N, Alivanis P. The role of melatonin in patients with chronic kidney disease undergoing haemodialysis. J Ren Care 2012; 38: 86-92.
182. [182] Karasek M, Szuflet A, Chrzanowski W, Zylinska K, Swietoslawski J. Circadian serum melatonin profiles in patients suffering from chronic renal failure. Neuro Endocrinol Lett 2002; 23 (Suppl 1): 97-102.
183. [183] Karasek M, Szuflet A, Chrzanowski W, Zylinska K, Swietoslawski J. Decreased melatonin nocturnal concentrations in hemodialyzed patients. Neuro Endocrinol Lett 2005; 26: 653-6.
184. [184] Koch BC, van der Putten K, Van Someren EJ, et al. Impairment of endogenous melatonin rhythm is related to the degree of chronic kidney disease (CREAM study). Nephrol Dial Transplant 2010a; 25: 513-9.
185. [185] Koch BC, Nagtegaal JE, Hagen EC, Wee PM, Kerkhof GA. Different melatonin rhythms and sleep-wake rhythms in patients on peri toneal dialysis, daytime hemodialysis and nocturnal hemodialysis. Sleep Med 2010b; 11: 242-6.
186. [186] Koch BC, Nagtegaal JE, Hagen EC, et al. The effects of melatonin on sleep-wake rhythm of daytime haemodialysis patients: a randomized, placebo-controlled, cross-over study (EMSCAP study). Br J Clin Pharmacol 2009; 67: 68-75.
187. [187] Kancheva R, Sulková S, Svára F, Hill M, Kanchev L, Zofková I. Increase of nocturnal melatonin levels in hemodialyzed patients after parathyroidectomy: a pilot study. Physiol Res 2008; 57(Suppl 1): S181-5.
188. [188] Geron R, Shurtz-Swirski R, Sela S, et al. Polymorphonuclear leukocyte priming in long intermittent nocturnal haemodialysis patients--is melatonin a player? Nephrol Dial Transplant 2006; 21: 3196-201.
189. [189] Herrera J, Nava M, Romero F, Rodríguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 2001; 37: 750-7.
190. [190] Labonia W, Rubio D, Arias C. Melatonin corrects reticuloendothelial blockade and iron status in haemodialysed patients. Nephrology (Carlton) 2005; 10: 583-7.
191. [191] Kadhim HM, Ismail SH, Hussein KI, et al. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin. J Pineal Res 2006; 41: 189-93.